Data gathered: May 17
Alternative Data for Apellis Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 23 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 27,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 37 | Sign up | Sign up | Sign up |
| Patents | 43 | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 22 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,087 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,617 | Sign up | Sign up | Sign up |
| Twitter Mentions | 43 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 815 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 779 | Sign up | Sign up | Sign up |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
| Price | $42.00 |
| Target Price | Sign up |
| Volume | 2,110,000 |
| Market Cap | $5.1B |
| Year Range | $37.14 - $72.47 |
| Dividend Yield | 0% |
| Revenue per Employee | $1,102,242 |
| Industry | Biotechnology |
In the news
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More InformationMay 16 - GlobeNewswire |
|
 |
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetMay 13 - Yahoo |
Apellis Pharmaceuticals: A Strong Buy on Syfovre’s Performance and Market PotentialMay 13 - TipRanks |
|
Apellis Pharmaceuticals enters into senior secured credit facilityMay 13 - Seeking Alpha |
|
 |
Apellis Pharmaceuticals Strives For Recovery Despite Syfovre SetbacksMay 13 - SeekingAlpha |
 |
Brokers Offer Predictions for Apellis Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:APLS)May 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 172M | 137M | 35M | -66M | -71M | -0.420 |
| Q4 '23 | 149M | 148M | 670,000 | -89M | -84M | -0.730 |
| Q3 '23 | 110M | 156M | -46M | -140M | -148M | -1.170 |
| Q2 '23 | 94M | 111M | -17M | -122M | -115M | -1.020 |
| Q1 '23 | 45M | 102M | -57M | -178M | -170M | -1.560 |
Insider Transactions View All
| Deschatelets Pascal filed to sell 1,115,983 shares at $44. May 9 '24 |
| Deschatelets Pascal filed to sell 1,116,083 shares at $42.8. May 9 '24 |
| Deschatelets Pascal filed to sell 1,138,555 shares at $42.2. May 9 '24 |
| Deschatelets Pascal filed to sell 1,115,983 shares at $54.9. April 9 '24 |
| Deschatelets Pascal filed to sell 1,120,711 shares at $54.1. April 9 '24 |
Similar companies
Read more about Apellis Pharmaceuticals (APLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Apellis Pharmaceuticals?
The Market Cap of Apellis Pharmaceuticals is $5.1B.
How Many People Work at Apellis Pharmaceuticals?
As of our latest update, Apellis Pharmaceuticals employed approximately 476 people worldwide. However, it's important to note that Apellis Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Apellis Pharmaceuticals' revenue per employee?
$1,102,242. To calculate Apellis Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Apellis Pharmaceuticals?
Currently, the price of one share of Apellis Pharmaceuticals stock is $42.00.
How can I analyze the APLS stock price chart for investment decisions?
The APLS stock price chart above provides a comprehensive visual representation of Apellis Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Apellis Pharmaceuticals shares. Our platform offers an up-to-date APLS stock price chart, along with technical data analysis and alternative data insights.
Does APLS offer dividends to its shareholders?
As of our latest update, Apellis Pharmaceuticals (APLS) does not offer dividends to its shareholders. Investors interested in Apellis Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Apellis Pharmaceuticals?
Some of the similar stocks of Apellis Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.